The EndoClot portfolio supports hemostasis and lifting in endoscopic submucosal dissection or resection in GI procedures. Olympus launched the EndoClot adhesive, the EndoClot polysaccharide hemostatic spray and the EndoClot submucosal injection solution.
EndoClot Plus developed the portfolio of GI solutions. The company expanded its distribution agreement with Olympus from the U.S. to EMEA in December 2022.
“We are excited to expand our global partnership with EndoClot Plus, Inc. The addition of their solutions to our portfolio allows us to strengthen our commitment to our customers as a full gastrointestinal solution provider for advanced therapeutic procedures,” said Stefanie Kaufung, EMEA business unit manager for GI endotherapy at Olympus. “Endoscopic resection and associated bleeding management are among Olympus’ core competencies. By contributing to safe treatment in gastrointestinal procedures, we aim to improve patient outcomes and hereby elevate the standard or care.”
About the Olympus EndoClot solutions
The EndoClot adhesive is a single-use medical device designed to seal lesions utilizing hemostatic polymer. This polymer offers durability thanks to its resistance to acids and bases in the GI tract. Its uses include at the end of a procedure to stop and control oozing bleeding. It may also prevent re-bleeding and protect the wound from irritation by acids and bases.
Olympus said the EndoClot polysaccharide hemostatic spray and submucosal injection solution utilize absorbable modified polymer (AMP) technology. This starch-derived AMP technology offers an excellent safety profile, according to the company.
EndoClot AMP particles absorb water from blood, causing a high concentration of platelets, red blood cells and coagulation proteins. This helps to accelerate the body’s clotting cascade. Olympus describes AMP particles as biocompatible, bioabsorbable, non-pyrogenic and starch-derived. They contain no animal or human components.
As of today, Olympus offers these EndoClot solutions commercially in Europe.